Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Jentadueto (linagliptin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• This summary is based on the review of one randomized controlled trial(s). ^[1]
• The probability of achieving normoglycemia was higher in the Linagliptin and Metformin (LM) group compared to the Metformin (M) group (OR 3.26, 95% CI: 1.55-6.84).
• The incidence of Type 2 Diabetes (T2D) was lower in the LM group compared to the M group (HR 4.0, 95% CI: 1.24-13.04, p = 0.020).
• The OGTT disposition index (DI), indicating pancreatic β-cell function, improved more significantly in the LM group across 6 and 24 months compared to the M group (p < 0.05).
• No major side effects were observed during the study, and no significant safety concerns or adverse effects were highlighted in the general population of prediabetic patients with impaired glucose tolerance and additional T2D risk factors.
• The study population consisted of prediabetic patients with impaired glucose tolerance and at least two additional T2D risk factors; in this subgroup, the Linagliptin and Metformin (LM) combination was more effective than Metformin alone in improving glucose metabolism, pancreatic β-cell function, and reducing T2D incidence.